Connect with us

Technology

Zoom Highest Growth in Brand Recognition for 2020 – 34% Increase

Published

on

Zoom 1

Zoom Highest Growth in Brand Recognition for 2020 – 34% Increase

Several brands experienced tremendous growth in 2020 due to the Coronavirus pandemic shifting demand in many industries. One of the brands that became a household name during the pandemic was video communications company Zoom. According to data presented by Trading Platforms, Zoom was the fastest-growing brand of 2020 with a 34% growth in brand recognition.

Zoom – Highest Growth In Brand Recognition 34%

COVID-19 shifted the world’s reality in more ways than one and this change can clearly be seen in consumer behaviour. Due to lockdowns across the globe, many of people’s normal routines were disrupted and many had to adjust to a “new normal.” The radical change meant there was a dramatic shift connected to pandemic-related behaviour such as the widespread use of food delivery services, at-home entertainment, work from home tools, cleaning products and pharmaceutical companies just to name a few.

One of the brands that benefited greatly from the sudden shift in demand is Video communications company Zoom. Zoom was founded in 2011 but it was not until 2020’s pandemic that it became a household name. A recent survey shows that Zoom experienced the most growth in brand recognition, with 34% more respondents indicating that they are familiar with the brand in Nov 2020 compared to January of the same year.

Zoom Fastest Growing Brand Among All Generations

The rise of Zoom’s brand recognition has helped catapult it into the fastest-growing brand of 2020. In January 2020, only 11% indicated that they would purchase from the brand but by November 2020 that number had risen to 26%, a growth of 15%. This growth was the highest recorded growth among brands.

Even more impressively, Zoom’s dominance crosses all generations as they also ranked the fastest growing brand among all age groups. Notably, Zoom saw the highest growth among Millenials (20%) and Gen X (20.3%) members, primarily fuelled by Zoom becoming a work from home necessity during the pandemic for many companies.

Most Of The Fastest Growing Brands Can Be Attributed To Pandemic Related Behaviour

Zoom was not the only company to benefit from the new normal as many other brands on the same list can also connect its growth to pandemic related behaviour. As people were forced to stay home, there was a notable increase in popularity for video streaming platforms as consumers looked for new ways to engage themselves.

NBC’s new streaming platform Peacock was just behind Zoom in the rankings with a recorded increase of 32% in brand recognition and a recorded brand growth of 11.5% – the second-highest after Zoom. Five other brands related to video-streaming (TikTok, HBO Max, Twitch, Tubi TV, Pluto TV,) also appear in the top 20 fastest growing brands of 2020.

Other brands on the list come from a range of industries, from cleaning products to pharmaceutical companies to also financial apps showing the clear effects of the COVID-19 pandemic.

CEO/Founder Investors King Ltd, a foreign exchange research analyst, contributing author on New York-based Talk Markets and Investing.com, with over a decade experience in the global financial markets.

Technology

Biotech Firm Launches Lassa Vaccine Trial in West Africa

Published

on

Lassa Fever

Biotech Firm Launches Lassa Vaccine Trial in West Africa

A biotechnology company, INOVIO, says the first participant in Lassa vaccine trial has been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever.

The clinical trial is being done in Ghana, the firm says, adding that INOVIO is focused on bringing to market precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer.

The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa Fever to be conducted in West Africa, where the infection is endemic.

The lead clinical Principal Investigator for LSV-002 is Professor Dr. Kwadwo A. Koram, an expert and specialist in tropical medicines and epidemiologist with more than 20 years of research experience, including malaria vaccines.

INO-4500 was also the first vaccine candidate for Lassa fever to enter human trials, PUNCH Healthwise reports.

Already, the Director-General of the Nigeria Centre for Disease Control, Dr. Chikwe Ihekweazu, has tweeted his commendation.

Said Ihekweazu, “Fantastic news. The urgency of now. A vaccine for Lassa fever. We have worked very hard with WHO, CEPI vaccines, ACEGID, BNITM_de and many others to put this on the global health agenda. We will keep pushing.”

According to a press release by the biotechnology company, INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership that leverages funding from public, private, philanthropic and civil society organisations to support research projects to develop vaccines against emerging infectious diseases.

INOVIO previously received a $56m grant from CEPI in 2018, under which the company is developing vaccine candidates for Lassa Fever and Middle East Respiratory Syndrome (MERS).

“INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phase 2 testing,” the press release stated.

The statement notes that INOVIO’s Phase 1B clinical trial, LSV-002, will enroll approximately 220 adult participants who are 18 – 50 years old, with the primary endpoints of evaluating safety and immunogenicity in an African population.

The dosing regimen involves two vaccinations at zero and 28 days with either 1.0 mg or 2.0 mg dosing levels. In addition to providing valuable insights on the INO-4500 safety and immunogenicity profile, this trial will inform dose selection for subsequent Phase 2 studies in West Africa.

Lassa fever is an animal-borne, acute hemorrhagic viral illness primarily observed in parts of West Africa.

Infection is spread through contact with infected rodents, as well as person-to-person transmission via bodily fluids (primarily in health care settings).

The disease can cause a range of outcomes, including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose and death.

Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, and is responsible for 10 – 16 percent of hospital admissions in the region. The virus is responsible for approximately 5,000 deaths annually.

Because of difficulties in diagnosing Lassa fever, the lack of standardised surveillance assays, and the remote nature of many of the areas in West Africa where outbreaks typically occur, the numbers of reported cases and deaths are very likely significantly lower than the actual numbers of cases and deaths.

Though the majority (about 80 percent) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. The case-fatality among patients hospitalized for Lassa fever is about 15 – 20 percent and, in some epidemics, case-fatality has reached 50 percent in hospitalized patients.

Up until now, there are no licensed vaccines or treatments specifically for Lassa fever.

Continue Reading

Technology

Google Says It Will Start Accepting Political Ads in US

Published

on

A logo is pictured at Google's European Engineering Center in Zurich

Google Says It Will Start Accepting Political Ads in US

Google has said it will resume accepting all political advertisements in the United States from Feb. 24.

The search giant disclosed in an email to advertisers on Monday.

Google paused all political advertisements in January when Trump’s mobs invaded U.S. Capitol.

Continue Reading

Technology

Elon Musk’s SpaceX Raised $850 Million at $74 Billion Valuation

Published

on

Elon Musk's SpaceX Raised $850 million at $74 billion valuation

Elon Musk’s SpaceX Raised $850 Million at $74 Billion Valuation

Elon Musk‘s SpaceX completed a $850 million equity funding round last week, according to people familiar with the funding.

According to the sources, SpaceX raised the $850 million at $419.99 per share or just 1 cent below the $420 price that Musk made infamous in 2018 when he announced he had enough funding to take Tesla private at that price.

The new funding round also represents an increase of around 60 percent in the firm’s valuation from its previous round in August, when SpaceX raised almost $2 billion at a $46 billion valuation.

SpaceX raised only a portion of the funding available in the marketplace, with one of the sources familiar with the funding saying, SpaceX received “insane demand” of around $6 billion in bids in three days.

 

Continue Reading

Trending